High serum concentration of low-density lipoprotein cholesterol (LDL-C) is a major risk factor for coronary heart disease. The efficacy of pantethine treatment on cardiovascular risk markers was investigated in a randomized, triple-blinded, placebo-controlled study, in a low to moderate cardiovascular disease (CVD) risk North American population eligible for statin therapy, using the National Cholesterol Education Program (NCEP) guidelines.
A total of 32 subjects were randomized to pantethine (600 mg/day from weeks 1 to 8 and 900 mg/day from weeks 9 to16) or placebo.
Compared with placebo, the participants on pantethine showed a significant decrease in total cholesterol at 16 weeks (P=0.040) and LDL-C at 8 and 16 weeks (P=0.020 and P=0.006, respectively), and decreasing trends in non-high-density lipoprotein cholesterol at week 8 and week 12 (P=0.102 and P=0.145, respectively) that reached significance by week 16 (P=0.042). An 11% decrease in LDL-C from baseline was seen in participants on pantethine, at weeks 4, 8, 12, and 16, while participants on placebo showed a 3% increase at week 16.
This decrease was significant between groups at weeks 8 (P=0.027) and 16 (P=0.010). The homocysteine levels for both groups did not change significantly from baseline to week 16. Coenzyme Q10 significantly increased from baseline to week 4 and remained elevated until week 16, in both the pantethine and placebo groups. After 16 weeks, the participants on placebo did not show significant improvement in any CVD risk end points.
This study confirms that pantethine lowers cardiovascular risk markers in low to moderate CVD risk participants eligible for statins according to NCEP guidelines.
This study confirms that pantethine lowers CVD risk markers in low to moderate CVD risk participants who are candidates for statins according to the NCEP guidelines.
Compared with placebo, pantethine-treated participants demonstrated significant declines in LDL-C, HDL-C, and TC levels after 16 weeks of treatment.
Moreover, unlike statins, which deplete CoQ10 to detrimental levels, both the pantethine and placebo groups significantly increased their CoQ10 levels above baseline. This study demonstrated that the TLC diet alone did not significantly affect lipid profiles but in conjunction with pantethine supplementation, significantly decreased lipid levels.
Supplementation with pantethine may therefore be considered as an optional adjunctive therapy for patients with low to moderate CVD risk.
Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3942300/
Read more
No comments:
Post a Comment